Interactions between pharmacologic and nonpharmacologic antiarrhythmic therapy

Area of Science:

• Cardiology
• Electrophysiology
• Pharmacology

Background:

• The optimal initial treatment strategy for serious ventricular arrhythmias, whether antiarrhythmic drugs or implantable cardioverter-defibrillators (ICDs), is not established.
• Many patients with ventricular arrhythmias are treated with both antiarrhythmic drugs and ICDs, though the frequency of this combined approach has decreased over time.

Purpose of the Study:

• To review the beneficial and adverse interactions between antiarrhythmic drugs and ICDs in patients with ventricular arrhythmias.
• To highlight the importance of careful consideration and monitoring when combining these treatment modalities.

Main Methods:

• Literature review and synthesis of existing studies on antiarrhythmic drug and ICD combination therapy.
• Analysis of reported benefits and drawbacks of combined pharmacologic and device therapy for ventricular arrhythmias.

Main Results:

• Beneficial interactions include improved hemodynamic tolerance, enhanced pacing/cardioversion success, reduced drug side effects, fewer arrhythmia episodes, and prevention of supraventricular arrhythmias.
• Adverse interactions involve slowed ventricular tachycardia detection, increased defibrillation/pacing thresholds, worsened hemodynamic tolerance, lengthened cardiac intervals, and reduced electrogram size, potentially leading to detection failure.

Conclusions:

• Combining antiarrhythmic drugs and ICDs can offer significant benefits but also presents considerable risks.
• Caution is advised when using both therapies concurrently, and repeat electrophysiologic testing is often required after initiating antiarrhythmic drug therapy in patients with an ICD to ensure efficacy and safety.